Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 487  

    Article Cited by others

CASE REPORT

177Lu-DOTATATE and177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment

Assadi Majid, Ahmadzadehfar Hojjat

Year : 2019| Volume: 18| Issue : 4 | Page no: 406-408

   This article has been cited by
 
1 PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports
M. J. M. Uijen,Y. H. W. Derks,R. I. J. Merkx,M. G. M. Schilham,J. Roosen,B. M. Privé,S. A. M. van Lith,C. M. L. van Herpen,M. Gotthardt,S. Heskamp,W. A. M. van Gemert,J. Nagarajah
European Journal of Nuclear Medicine and Molecular Imaging. 2021;
[Pubmed]  [Google Scholar] [DOI]
2 Head-to-Head Comparison of 68Ga-PSMA-11 and 131I in the Follow-Up of Well-Differentiated Metastatic Thyroid Cancer: A New Potential Theragnostic Agent
Quetzali Pitalua-Cortes, Francisco Osvaldo García-Perez, Joel Vargas-Ahumada, Sofia Gonzalez-Rueda, Edgar Gomez-Argumosa, Eleazar Ignacio-Alvarez, Irma Soldevilla-Gallardo, Liliana Torres-Agredo
Frontiers in Endocrinology. 2021; 12
[Pubmed]  [Google Scholar] [DOI]
3 Next-Generation Molecular Imaging of Thyroid Cancer
Yuchen Jin,Beibei Liu,Muhsin H. Younis,Gang Huang,Jianjun Liu,Weibo Cai,Weijun Wei
Cancers. 2021; 13(13): 3188
[Pubmed]  [Google Scholar] [DOI]
4 New Frontiers in Molecular Imaging Using Peptide-Based Radiopharmaceuticals for Prostate Cancer
Xin Li,Huawei Cai,Xiaoai Wu,Li Li,Haoxing Wu,Rong Tian
Frontiers in Chemistry. 2020; 8
[Pubmed]  [Google Scholar] [DOI]

 

Read this article